Clinical Trial Update: Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating ofatumumab as primary therapy for chronic graft-versus-host disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Graft Versus Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-11-12